You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生製藥(1177.HK)領藥品股普跌 帶量採購擬中選藥品價格大降
格隆匯 09-25 16:30
格隆匯9月25日丨港股市場藥品股普跌,其中,中國生物製藥(1177.HK)跌5.34%,復星醫藥跌4.61%,石藥集團跌3.69%。在國家醫保局等部門指導下,參與藥品帶量採購的擴圍的25個省份和新疆生產建設兵團24日在上海開展聯合招採,產生了擬中選結果。聯合採購辦公室昨日發佈公告顯示,25個“4+7”試點藥品擴圍採購全部成功,價格都降低到不高於“4+7”試點中選價格的水平,羣眾費用負擔將大幅度降低。擬中選結果將於今日在上海陽光醫藥採購網公佈,公示一週後正式發佈。本次聯盟採購共有77家企業參與,產生擬中選企業45家,擬中選產品60個。與聯盟地區2018年最低採購價相比,擬中選價平均降幅59%;與“4+7”試點中選價格水平相比,平均降幅25%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account